Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BETTER: Ezetimibe add-on in very high-risk ASCVD
NCT05761444Phase 4Completed
- Sponsor
- Organon & Co.
- Start
- Jul 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ezetimibe in atherosclerotic cardiovascular disease (ASCVD), sponsored by Organon & Co.. Started Jul 2023; status: completed.
02
Drugs
ezetimibe
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT05761444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05761444.